Burnham-Marusich Amanda R, Ezeanolue Chinenye O, Obiefune Michael C, Yang Wei, Osuji Alice, Ogidi Amaka G, Hunt Aaron T, Patel Dina, Ezeanolue Echezona E
Department of Microbiology and Immunology, University of Nevada School of Medicine, Reno, Nev., USA.
Public Health Genomics. 2016;19(5):298-306. doi: 10.1159/000448914. Epub 2016 Sep 10.
BACKGROUND/AIMS: Sickle cell disease (SCD) is a life-threatening, autosomal recessive blood disorder prevalent in sub-Saharan Africa. We identified the prevalence of sickle cell trait (SCT) among pregnant women and their male partners in Enugu State, Nigeria, and determined the accuracy of self-reported sickle cell status and its reliability for identifying high-risk newborns for targeted screening.
We conducted a nested cohort study of expectant parents enrolled in the Healthy Beginning Initiative (HBI). The HBI is a cluster-randomized trial of a congregation-based approach designed to increase HIV testing. Participants completed a survey regarding self-awareness of their sickle cell genotype and consented to genotype screening by cellulose acetate electrophoresis.
SCT prevalence (HbAS) was 22% (746/3,371). Only 50% of participants provided an accurate self-report. Self-report accuracy was significantly different (p < 0.0001) between individuals who reported having SCT or SCD (61% accuracy) versus those who reported not having SCT or SCD (86% accuracy). Demographic variables including gender, age, household size, employment, education, and home location were significantly associated with providing an accurate self-report.
Low numbers of accurate parental self-reports, coupled with a high SCT prevalence in Nigeria, could limit the efficacy of targeted newborn screening. However, our data indicate that it is feasible to integrate sickle cell screening for pregnant women with existing, community-based health care programs developed by the President's Emergency Plan for AIDS Relief (PEPFAR), such as the HBI. Expanding screening programs could enable the development of targeted newborn screening based on maternal genotype that could identify all newborns with SCD in resource-limited settings.
背景/目的:镰状细胞病(SCD)是一种危及生命的常染色体隐性血液疾病,在撒哈拉以南非洲地区普遍存在。我们确定了尼日利亚埃努古州孕妇及其男性伴侣中镰状细胞性状(SCT)的患病率,并确定了自我报告的镰状细胞状态的准确性及其在识别高危新生儿进行靶向筛查方面的可靠性。
我们对参加健康开端倡议(HBI)的准父母进行了一项嵌套队列研究。HBI是一项基于群体的方法的整群随机试验,旨在增加艾滋病毒检测。参与者完成了一项关于其镰状细胞基因型自我认知的调查,并同意通过醋酸纤维素电泳进行基因型筛查。
SCT患病率(HbAS)为22%(746/3371)。只有50%的参与者提供了准确的自我报告。报告患有SCT或SCD的个体(准确率61%)与报告未患有SCT或SCD的个体(准确率86%)之间的自我报告准确性存在显著差异(p<0.0001)。包括性别、年龄、家庭规模、就业、教育和家庭住址在内的人口统计学变量与提供准确的自我报告显著相关。
准确的父母自我报告数量较少,加上尼日利亚SCT患病率较高,可能会限制靶向新生儿筛查的效果。然而,我们的数据表明,将孕妇镰状细胞筛查与总统艾滋病紧急救援计划(PEPFAR)制定的现有社区卫生保健项目(如HBI)相结合是可行的。扩大筛查项目可以推动基于母亲基因型的靶向新生儿筛查的发展,从而在资源有限的环境中识别所有患有SCD的新生儿。